Geron is also testing the drug for myelofibrosis (MF), another form of bone marrow cancer, and expects data from the phase 3 IMpactMF trial of imetelstat in relapsed/refractory MF in 2024.

Shares of Geron (NASDAQ:GERN) plunged 30% Wednesday after management reportedly indicated on the company's Q4 earnings call that sales of its lead drug Rytelo appear to be slowing. For Q4 ...

Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected. The biopharmaceutical company had a quarterly loss of $25.4 million, or 4 cents a ...

Analysts' ratings for Geron GERN over the last quarter vary from bullish to bearish, as provided by 4 analysts. The following table provides a quick overview of their recent ratings, highlighting ...

Geron (GERN) Corporation announced that John “Chip” A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new ...

Hello and welcome to the Geron fourth quarter and full year 2024 earnings call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a ...

Geron (GERN) Corporation announced that the European Commission has granted marketing authorization for RYTELO as a monotherapy for the treatment of adult patients with transfusion-dependent ...